PL2131845T3 - Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie - Google Patents

Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie

Info

Publication number
PL2131845T3
PL2131845T3 PL08717228T PL08717228T PL2131845T3 PL 2131845 T3 PL2131845 T3 PL 2131845T3 PL 08717228 T PL08717228 T PL 08717228T PL 08717228 T PL08717228 T PL 08717228T PL 2131845 T3 PL2131845 T3 PL 2131845T3
Authority
PL
Poland
Prior art keywords
phenyl
polymorphs
morpholin
isoxazole
ylmethyl
Prior art date
Application number
PL08717228T
Other languages
English (en)
Polish (pl)
Inventor
Martin James Drysdale
Brian William Dymock
Christoph Krell
Michael Mutz
Holger Petersen
Weijia Zheng
Original Assignee
Novartis Ag
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2131845(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag
Publication of PL2131845T3 publication Critical patent/PL2131845T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL08717228T 2007-03-01 2008-02-28 Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie PL2131845T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
EP08717228A EP2131845B1 (en) 2007-03-01 2008-02-28 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide mesylate, hydrates and polymorphs thereof, and formulations comprising these forms
PCT/EP2008/052443 WO2008104595A1 (en) 2007-03-01 2008-02-28 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number Publication Date
PL2131845T3 true PL2131845T3 (pl) 2012-09-28

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08717228T PL2131845T3 (pl) 2007-03-01 2008-02-28 Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie

Country Status (40)

Country Link
US (3) US8163747B2 (enExample)
EP (2) EP2545921A3 (enExample)
JP (1) JP2010520176A (enExample)
KR (1) KR20090122218A (enExample)
CN (2) CN101636162A (enExample)
AR (1) AR065519A1 (enExample)
AT (1) ATE552836T1 (enExample)
AU (1) AU2008220800B2 (enExample)
BR (1) BRPI0807992A2 (enExample)
CA (1) CA2678043A1 (enExample)
CL (1) CL2008000618A1 (enExample)
CO (1) CO6210828A2 (enExample)
CR (1) CR10989A (enExample)
CY (1) CY1113805T1 (enExample)
DK (1) DK2131845T3 (enExample)
DO (1) DOP2009000209A (enExample)
EA (1) EA017075B1 (enExample)
EC (1) ECSP099602A (enExample)
ES (1) ES2384906T3 (enExample)
GE (1) GEP20115309B (enExample)
GT (1) GT200900236A (enExample)
HR (1) HRP20120535T1 (enExample)
IL (1) IL200401A0 (enExample)
MA (1) MA31204B1 (enExample)
MX (1) MX2009009233A (enExample)
NI (1) NI200900161A (enExample)
NZ (1) NZ578854A (enExample)
PA (1) PA8771101A1 (enExample)
PE (1) PE20090166A1 (enExample)
PL (1) PL2131845T3 (enExample)
PT (1) PT2131845E (enExample)
RS (1) RS52351B (enExample)
SI (1) SI2131845T1 (enExample)
SM (1) SMAP200900080A (enExample)
TN (1) TN2009000357A1 (enExample)
TW (1) TW200844102A (enExample)
UA (1) UA101950C2 (enExample)
UY (1) UY30943A1 (enExample)
WO (1) WO2008104595A1 (enExample)
ZA (1) ZA200905417B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
WO2010060854A1 (en) 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
BR112012017994B8 (pt) * 2010-01-21 2020-12-08 Aprea Ab composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
JP2013519727A (ja) * 2010-02-17 2013-05-30 イルドン ファーム シーオー.,エルティーディー. 新規の5員複素環誘導体及びその製造方法
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
SI2131845T1 (sl) 2013-02-28
BRPI0807992A2 (pt) 2014-06-17
DOP2009000209A (es) 2009-09-15
WO2008104595A1 (en) 2008-09-04
UA101950C2 (ru) 2013-05-27
GEP20115309B (en) 2011-10-25
PE20090166A1 (es) 2009-03-14
TN2009000357A1 (en) 2010-12-31
ZA200905417B (en) 2010-05-26
NI200900161A (es) 2010-07-27
CR10989A (es) 2010-03-01
ATE552836T1 (de) 2012-04-15
CL2008000618A1 (es) 2008-09-12
AU2008220800A1 (en) 2008-09-04
CN101636162A (zh) 2010-01-27
DK2131845T3 (da) 2012-07-16
EP2545921A3 (en) 2013-04-10
MA31204B1 (fr) 2010-02-01
MX2009009233A (es) 2010-06-02
EP2545921A2 (en) 2013-01-16
RS52351B (sr) 2012-12-31
KR20090122218A (ko) 2009-11-26
CY1113805T1 (el) 2016-07-27
ECSP099602A (es) 2009-12-28
US20120172592A1 (en) 2012-07-05
PA8771101A1 (es) 2009-02-09
US8487095B2 (en) 2013-07-16
EA017075B1 (ru) 2012-09-28
CN102302500A (zh) 2012-01-04
NZ578854A (en) 2012-03-30
ES2384906T3 (es) 2012-07-13
CO6210828A2 (es) 2010-10-20
EP2131845B1 (en) 2012-04-11
GT200900236A (es) 2011-09-14
US20130296556A1 (en) 2013-11-07
US20100093732A1 (en) 2010-04-15
SMAP200900080A (it) 2010-01-19
UY30943A1 (es) 2008-10-31
AR065519A1 (es) 2009-06-10
PT2131845E (pt) 2012-07-10
EP2131845A1 (en) 2009-12-16
EA200901141A1 (ru) 2010-04-30
TW200844102A (en) 2008-11-16
HK1139073A1 (en) 2010-09-10
AU2008220800B2 (en) 2012-02-16
JP2010520176A (ja) 2010-06-10
IL200401A0 (en) 2010-04-29
CA2678043A1 (en) 2008-09-04
US8163747B2 (en) 2012-04-24
HRP20120535T1 (hr) 2012-07-31

Similar Documents

Publication Publication Date Title
SI2131845T1 (sl) Mesilat etilamida 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin- 4-ilmetilfenil)-izoksazol-3-karboksilne kisline, hidrati in polimorfi le-tega in formulacije, ki vsebujejo te oblike
NO2022013I1 (en) Finerenone and its salts, solvates and solvates of the salts thereof
SI2217578T1 (sl) (1,2,4)triazolo(1,5-a)piridinske in (1,2,4)triazolo(1,5-c)pirimidinske spojine in njihova uporaba
HRP20170634T1 (hr) Kristalni oblici od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
ZA200804762B (en) 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
MA28994B1 (fr) Composition immunogene
IL195511A0 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
PL1959948T3 (pl) Metanosulfonian proleku lewodopy, jego kompozycje, oraz jego zastosowania
IL202073A0 (en) Substituted oxazolidinones and the use thereof
IL196959A0 (en) Insecticidal isoxazolines
ATE462444T1 (de) Immunogene zusammensetzung
IL216349A (en) Annals 4– (1-carboxy-ethylcarbamoyl) –4– (5– [1,12] diethylan-3-ram-pentanoylamino) -butyric acid and preparations containing them
LT3210610T (lt) Kompozicijos, turinčios triazonų ir geležies
PT2225238E (pt) Derivados de amidas do ácido 6,7-di-hidro-5h-imidazo[1,2- a]imidazol-3-carboxílico
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
ZA200904165B (en) Novel gene disruptions, compositions and methods relating thereto
ZA200808498B (en) Novel gene disruptions,compositions and methods relating thereto
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
ZA200708818B (en) Antibacterial 5,5-disubstituted 3,3-dialkoxy-2,2-dihydroxy-1,1-biphenyl compounds and related methods
SI1951697T1 (sl) Substituirani 5-fenil-3,6-dihidro-2-okso-6h-(1,3,4)tiadiazini
FI20041235A0 (fi) Menetelmä rautaoksihydroksia sisältävän adsorbenttimateriaalin valmistamiseksi, adsorbenttimateriaali sekä sen käyttö
ZA200903981B (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethyl-benzamide
IL185166A0 (en) Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing same and use thereof